AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts....
+See More2023-09-07 11:30:00 Thursday ET
Michael Woodford provides the theoretical foundations of monetary policy rules in ever more efficient financial markets. Michael Woodford (2003)
2025-06-21 10:25:00 Saturday ET
Former New York Times science author and Harvard psychologist Daniel Goleman explains why emotional intelligence can serve as a more important critical succ
2019-04-23 19:45:00 Tuesday ET
Income and wealth concentration follows the ebbs and flows of the business cycle in America. Economic inequality not only grows among people, but it also gr
2019-07-21 09:37:00 Sunday ET
Facebook introduces a new cryptocurrency Libra as a fresh medium of exchange for e-commerce. Libra will be available to all the 2 billion active users on Fa
2018-10-27 09:34:00 Saturday ET
U.S. automobile and real estate sales decline despite higher consumer confidence and low unemployment as of October 2018. This slowdown arises from the curr
2018-01-21 07:25:00 Sunday ET
As he refrains from using the memorable phrase *irrational exuberance* to assess bullish investor sentiments, former Fed chairman Alan Greenspan discerns as